Evidence map›Paper›PMID 31651370›Full record

ArticleTrials2019

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).

Katharina Dörr, Michael Kammer, Roman Reindl-Schwaighofer, Matthias Lorenz, Christian Loewe, Rodrig Marculescu, Reinhold Erben, Rainer Oberbauer

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03182699 (Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03182699 phase4completednot on this map

Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial

TypeinterventionalSponsorRainer OberbauerRan2017 to 2019Enrolled62ConditionsSecondary Hyperparathyroidism, Chronic Kidney Disease Requiring Chronic Dialysis, Left Ventricular HypertrophyArmscardiac MRI, echocardiography with strain, Laboratory tests, Body composition monitoring, lung ultrasound
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katharina DörrDepartment of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0003-3325-8780
Michael KammerDepartment of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Roman Reindl-SchwaighoferDepartment of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Matthias LorenzVienna Dialysis Center, Kapellenweg 37, 1220, Vienna, Austria.
Christian LoeweDivision of Cardiovascular and Interventional Radiology, Department of Bioimaging and Image-Guided Intervention, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Rodrig MarculescuLaboratory Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Reinhold ErbenPhysiology, Pathophysiology, and Experimental Endocrinology, VetMed Vienna, Veterinärplatz 1, Vienna, Austria.
Rainer OberbauerDepartment of Nephrology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. Rainer.oberbauer@meduniwien.ac.at.
Medical University of Vienna · ATStatistics Austria · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibroblast growth factor 23 (FGF23) is associated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease, and calcimimetic therapy reduces plasma concentrations of FGF23. It remains unknown whether treatment with the calcimimetic etelcalcetide (ETL) reduces LVH in patients on hemodialysis. METHODS/

designThis single-blinded randomized trial of 12 months duration will test the effects of ETL compared with alfacalcidol on LVH and cardiac fibrosis in maintenance hemodialysis patients with secondary hyperparathyroidism. Both treatment regimens will be titrated to equally suppress secondary hyperparathyroidism while alfacalcidol treatment causes an increase and ETL a decrease in FGF23, respectively. Patients treated thrice weekly with hemodialysis for ≥ 3 months and ≤ 3 years with parathyroid hormone levels ≥ 300 pg/ml and LVH will be enrolled in the study. The primary study endpoint is change from baseline to 12 months in left ventricular mass index (LVMI; g/m DISCUSSION: The causal inference and pathophysiology of LVH regression by FGF23 reduction using calcimimetic treatment has not yet been shown. This intervention study has the potential to discover a new strategy for the treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis. It might be speculated that successful treatment of cardiac morphology will also reduce the risk of cardiac death in this population.

trial registrationEuropean Clinical Trials Database, EudraCT number 2017-000222-35; ClinicalTrials.gov, NCT03182699 . Registered on.

Indexed as

AustriaBiomarkersCalcimimetic AgentsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFibrosisHumansHyperparathyroidism, SecondaryHypertrophy, Left VentricularMalePeptidesRandomized Controlled Trials as TopicReceptors, Calcium-SensingRenal DialysisSingle-Blind MethodBiomarkersCalcimimetic AgentsCASR protein, humanetelcalcetide hydrochlorideFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsPeptidesReceptors, Calcium-SensingAlfacalcidolEtelcalcetideFGF23HemodialysisLeft ventricular hypertrophySecondary hyperparathyroidism

Identifiers

PMID31651370
PMCPMC6813957
OpenAlexW2981770025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.